Cdc7 Inhibitors

Cdc7 inhibitors represent a diverse class of chemicals designed to specifically target and inhibit the kinase activity of Cdc7, a key regulator of DNA replication initiation. XL413, an ATP-competitive inhibitor, directly binds to the ATP pocket of Cdc7, disrupting its kinase activity and disrupting the initiation of DNA replication. This interference results in cell cycle arrest and inhibition of cell proliferation. PHA-767491, a pyrrolopyridine derivative, directly inhibits Cdc7 kinase activity, disrupting its role in DNA replication initiation. This direct inhibition leads to cell cycle arrest and suppression of DNA synthesis. TAK-931, a highly selective Cdc7 inhibitor, directly targets and inhibits the kinase activity of Cdc7, leading to cell cycle arrest and hindrance of cancer cell proliferation. LY3177833, another potent and selective Cdc7 kinase inhibitor, directly targets Cdc7, inhibiting its kinase activity and disrupting the initiation of DNA replication. This direct inhibition results in cell cycle arrest and inhibition of cancer cell proliferation. PHA-848125, a pyrrolopyridine-based inhibitor, directly targets Cdc7, inhibiting its kinase activity and disrupting DNA replication initiation, leading to cell cycle arrest and suppression of cancer cell proliferation. CMK, YKL-5-124, LY3143921, and ICEC0942 are small molecule inhibitors that directly target Cdc7, inhibiting its kinase activity and disrupting the initiation of DNA replication. These direct inhibitions lead to cell cycle arrest and hinder the proliferation of cancer cells by interfering with DNA synthesis. XL413 Hydrochloride, PHA-767491 hydrochloride, and LY3177833 Hydrochloride are salt forms of their respective compounds with similar mechanisms of action. These hydrochloride salts maintain the inhibitory activity against Cdc7, resulting in cell cycle arrest and inhibition of cancer cell proliferation.